AGTI vs. IMNM, AKRO, OCUL, NVCR, SLNO, ATRC, DAWN, KNSA, ESTA, and VIR
Should you be buying Agiliti stock or one of its competitors? The main competitors of Agiliti include Immunome (IMNM), Akero Therapeutics (AKRO), Ocular Therapeutix (OCUL), NovoCure (NVCR), Soleno Therapeutics (SLNO), AtriCure (ATRC), Day One Biopharmaceuticals (DAWN), Kiniksa Pharmaceuticals (KNSA), Establishment Labs (ESTA), and Vir Biotechnology (VIR). These companies are all part of the "medical" sector.
Immunome (NASDAQ:IMNM) and Agiliti (NYSE:AGTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Immunome has a net margin of 0.00% compared to Immunome's net margin of -1.65%. Immunome's return on equity of 6.47% beat Agiliti's return on equity.
44.6% of Immunome shares are held by institutional investors. Comparatively, 99.1% of Agiliti shares are held by institutional investors. 20.0% of Immunome shares are held by insiders. Comparatively, 4.2% of Agiliti shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Agiliti has higher revenue and earnings than Immunome. Agiliti is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Immunome has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Agiliti has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Immunome presently has a consensus target price of $24.50, suggesting a potential downside of 4.00%. Agiliti has a consensus target price of $14.17, suggesting a potential upside of 39.99%. Given Immunome's higher possible upside, analysts clearly believe Agiliti is more favorable than Immunome.
In the previous week, Agiliti had 5 more articles in the media than Immunome. MarketBeat recorded 10 mentions for Agiliti and 5 mentions for Immunome. Agiliti's average media sentiment score of 1.10 beat Immunome's score of 0.37 indicating that Immunome is being referred to more favorably in the media.
Agiliti received 22 more outperform votes than Immunome when rated by MarketBeat users. However, 64.52% of users gave Immunome an outperform vote while only 58.33% of users gave Agiliti an outperform vote.
Summary
Agiliti beats Immunome on 10 of the 18 factors compared between the two stocks.
Get Agiliti News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools